Inhaler misuse is common among both patients and healthcare providers. It contributes to disparity in healthcare among both asthma and COPD.
It's been the dirty little secret in respiratory medicine for decades.
...and it hasn't gotten any better until..
Reducing Disparity in Respiratory Care
"Improving access to tools which enhance medication delivery, improving care and treatment, are a key element of intervention strategies to reduce disparity in asthma care."
These tools should be easily accessible and affordable, without technological barriers to use (no cellphone, app, or internet connection )
90% OF PATIENTS FAIL TO OBTAIN THE INTENDED BENEFITS FROM INHALED MEDICATIONS DUE TO INHALER MISUSE
85% OF HEALTHCARE PROVIDERS ARE UNABLE TO DEMONSTRATE OR INSTRUCT PROPER INHALER TECHNIQUE
OVER $7 BILLION DOLLARS ANNUALLY IS ATTRIBUTED TO INHALER MISUSE
The patient experience is at the core of all that we do at Abithas, Inc.. Our main goal is to use keep it simple technology solutions to address the problems and concerns that people have using common metered-dose inhalers ("MDIs") and rigid, tube type spacer devices.
Up to 87% of MDI users fail to use current rigid, tube type spacers regularly. Ask yourself, why wouldn't someone use a device if they clearly benefit from it?. That's why we developed the InspirEase®HFA option.
Using an MDI with the iHFA®, people have confidence, knowing that every puff of medication gets into their lungs, each and every time. The iHFA® is designed to take the worry and problem out of using common, metered-dose inhalers.
Get in touch with us to learn more about the InspirEase®HFA.
Simply attach a press and breathe MDI to the InspirEase®HFA,
open the device, trigger the inhaler, and breathe in.
As you breathe in, the bag collapses, and a whistle sounds if you inhaled too fast
As you breathe in, the bag collapses without making a sound
Edward Lisberg, MD FCCP CPI
Abithas, Inc. is leading innovation in patient-centered, inhaler spacer technology. Founded by Edward Lisberg, MD FCCP CPI, a respiratory specialist with decades of experience as a Principal Investigator (over 160 phase 2 and 3 clinical trials), and as a leading clinician in asthma and COPD.
Seeing patients struggle with using inhalers and current Spacers, hear him tell why he developed the InspirEase®HFA.
Every time that you see someone with asthma or COPD use an inhaler, ask yourself this:
"How do they know that they got the full puff of medication
from their inhaler into their lungs?"
Note: this device is investigational and not available for commercial sale
Are you an Angel Investor? Abithas, Inc. is certified as a Qualified New Business Venture (QNBV) under the Illinois Angel Investment Tax Credit Program (#116J). Investors in companies that are certified as QNBVs can receive a state tax credit equal to 25% of their investment (up to $2 million).Accredited investors seeking information use the form below to contact us.